Selective estrogen-induced apoptosis in breast cancer

Steroids

Volumn 90, Issue , 2014, Pages 60-70

  Obiorah, Ifeyinwa E ^a   Fan, Ping ^a   Sengupta, Surojeet ^a   Jordan, V Craig ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Apoptosis; Breast cancer; Endoplasmicreticulum stress; Estradiol; Inflammation; Unfolded protein response

Indexed keywords

ESTRADIOL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; ESTROGEN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CELL POPULATION; CELL PROLIFERATION; CELL SELECTION; CLINICAL PRACTICE; CONFORMATION; ENDOPLASMIC RETICULUM STRESS; ESTROGEN ACTIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; IN VITRO STUDY; LONG TERM CARE; MCF 7 CELL LINE; ONCOGENE SRC; PROTEIN UNFOLDING; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; RECEPTORS, ESTROGEN;

EID: 84908692657     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2014.06.003     Document Type: Review

References (87)

1. V.C. Jordan A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention Cancer Res 69 2009 1243 1254
2. V.C. Jordan, and A.M. Brodie Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer Steroids 72 2007 7 25
3. C. Davies, J. Godwin, R. Gray, M. Clarke, D. Cutter, S. Darby, P. McGale, H.C. Pan, C. Taylor, and Y.C. Wang Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 2011 771 784
4. C. Davies, H. Pan, J. Godwin, R. Gray, R. Arriagada, and V. Raina Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 2013 805 816
5. M. Dowsett, J. Cuzick, J. Ingle, A. Coates, J. Forbes, and J. Bliss Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol 28 2010 509 518
6. A. Lacassagne Hormonal pathogenesis of adenocarcinoma of the breast Am J Cancer 27 1936 217 228
7. A. Lacassagne A comparative study of the carcinogenic action of certain oestrogenic hormones Am J Cancer 28 1936 735 740
8. V.C. Jordan The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole Breast Cancer Res Treat 11 1988 197 209
9. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, and W.M. Cronin Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
10. B. Fisher, J.P. Costantino, D.L. Wickerham, R.S. Cecchini, W.M. Cronin, and A. Robidoux Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study J Natl Cancer Inst 97 2005 1652 1662
11. V.G. Vogel, J.P. Costantino, D.L. Wickerham, W.M. Cronin, R.S. Cecchini, and J.N. Atkins Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2006 2727 2741
12. V.G. Vogel, J.P. Costantino, D.L. Wickerham, W.M. Cronin, R.S. Cecchini, and J.N. Atkins Update of the national surgical adjuvant breast and bowel project study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer Cancer Prev Res (Phila) 3 2010 696 706
13. S. Shafie Estrogen and the growth of breast cancer: new evidence suggests indirect action Science 209 1980 701 702
14. Y. Berthois, J.A. Katzenellenbogen, and B.S. Katzenellenbogen Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture Proc Natl Acad Sci USA 83 1986 2496 2500
15. A. Haddow, J.M. Watkinson, and E. Patterson Influence of synthetic oestrogens upon advanced malignant disease BMJ 2 1944 393 398
16. A. Haddow, and A. David Karnosky memorial lecture: thoughts on chemical therapy Cancer Res 26 1970 737 754
17. B. Stoll Palliation by castration or by hormone administration B. Stoll, Breast cancer management early and late 1977 William Herman Medical Books Ltd. London, UK 133 146
18. B.J. Kennedy Hormone therapy for advanced breast cancer Cancer 18 1965 1551 1557
19. B.J. Kennedy, and J.H. Brown Combined estrogenic and androgenic hormone therapy in advanced breast cancer Cancer 18 1965 431 435
20. B.J. Kennedy Endocrine therapy of breast cancer JAMA 200 1967 971 972
21. M. Cole, C. Jones, and I. Todd A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474 Br J Cancer 25 1971 270 275
22. J. Ingle, D. Ahmann, S. Green, J. Edmonson, H. Bisel, and L. Kvols Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer N Engl J Med 304 1981 16 21
23. C.K. Osborne, E.B. Coronado, and J. Robinson Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy Eur J Cancer Clin Oncol 23 1987 1189 1196
24. M.M. Gottardis, and V.C. Jordan Develoment of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term anti-estrogen administration Cancer Res 48 1988 5183 5187
25. M.M. Gottardis, R.J. Wagner, E.C. Borden, and V.C. Jordan Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro Cancer Res 49 1989 4765 4769
26. A. Howell, D.J. Dodwell, H. Anderson, and J. Redford Response after withdrawal of tamoxifen and progestogens in advanced breast cancer Ann Oncol 3 1992 611 617
27. P.A. Canney, T. Griffiths, T.N. Latief, and T.J. Priestman Clinical significance of tamoxifen withdrawal response Lancet 329 1987 36
28. A. Howell, J.F.R. Robertson, J. Quaresma Albano, A. Aschermannova, L. Mauriac, and U.R. Kleeberg Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 2002 3396 3403
29. C.K. Osborne, J. Pippen, S.E. Jones, L.M. Parker, M. Ellis, and S. Come Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 2002 3386 3395
30. D.M. Wolf, and V.C. Jordan A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy Recent Results Cancer Res 127 1993 23 33
31. K. Yao, E. Lee, D. Bentrem, G. England, J. Schafer, and R. O'Regan Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice Clin Cancer Res 6 2000 2028 2036
32. C. Osipo, C. Gajdos, H. Liu, B. Chen, and V.C. Jordan Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer J Natl Cancer Inst 95 2003 1597 1608
33. H. Liu, E. Lee, C. Gajdos, S. Pearce, B. Chen, and C. Osipo Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo J Natl Cancer Inst 95 2003 1586 1597
34. C. Osipo, K. Meeke, D. Cheng, A. Weichel, A. Bertucci, and H. Liu Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer Int J Oncol 30 2007 509
35. G.M. Balaburski, R.C. Dardes, M. Johnson, B. Haddad, F. Zhu, and E.A. Ross Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance Int J Oncol 37 2010 387 398
36. S.Y. Jiang, D. Wolf, J. Yingling, C. Chang, and V.C. Jordan An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol Mol Cell Endocrinol 90 1992 77 86
37. J.J. Pink, S.-Y. Jiang, M. Fritsch, and V.C. Jordan An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein Cancer Res 55 1995 2583 2590
38. R.X. Song, G. Mor, F. Naftolin, R.A. McPherson, J. Song, and Z. Zhang Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol J Natl Cancer Inst 93 2001 1714 1723
39. J.S. Lewis, C. Osipo, K. Meeke, and V.C. Jordan Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal J Steroid Biochem Mol Biol 94 2005 131 141
40. J.S. Lewis, K. Meeke, C. Osipo, E. Ross, N. Kidawi, and T. Li Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation J Natl Cancer Inst 97 2005 1746 1759
41. E. Ariazi, H. Cunliffe, J.S. Lewis-Wambi, M. Slifker, A. Willis, and P. Ramos Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time Proc Natl Acad Sci USA 108 2011 18879 18886
42. E. Sweeney, and P. Fan Jordan VC Mechanisms underlying differential response to estrogen-induced apoptosis in long-term estrogen-deprived breast cancer cells, Int J Oncol 44 2014 1529 1538
43. D.M. Townsend, K.D. Tew, and H. Tapiero The importance of glutathione in human disease Biomed Pharmacother 57 2003 145 155
44. J. Lewis-Wambi, H. Kim, C. Wambi, R. Patel, J. Pyle, and A. Klein-Szanto Buthionine sulfoximine sensitizes anti-hormone-resistant human breast cancer cells to estrogen-induced apoptosis Breast Cancer Res 10 2008 R104
45. J.S. Lewis-Wambi, R. Swaby, H. Kim, and V.C. Jordan Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer J Steroid Biochem Mol Biol 2009 33 39
46. V.C. Jordan, J.M. Schafer, A.S. Levenson, H. Liu, K.M. Pease, and L.A. Simons Molecular classification of estrogens Cancer Res 61 2001 6619 6623
47. J.M. Schafer, H. Liu, D.J. Bentrem, J.W. Zapf, and V.C. Jordan Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351 Cancer Res 60 2000 5097 5105
48. A.M. Brzozowski, A.C.W. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, and O. Engstrom Molecular basis of agonism and antagonism in the oestrogen receptor Nature 389 1997 753 758
49. A.K. Shiau, D. Barstad, P.M. Loria, L. Cheng, P.J. Kushner, and D.A. Agard The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen Cell 95 1998 927 937
50. P.Y. Maximov, C.B. Myers, R.F. Curpan, J.S. Lewis-Wambi, and V.C. Jordan Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen J Med Chem 53 2010 3273 3283
51. S. Sengupta, I. Obiorah, P.Y. Maximov, R. Curpan, and V.C. Jordan Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells B J Pharmacol 169 2013 167 178
52. I. Obiorah, S. Sengupta, R. Curpan, and V.C. Jordan Defining the conformation of the estrogen receptor complex that controls estrogen induced apoptosis in breast cancer Mol Pharmacol 85 2014 789 799
53. Obiorah I, Jordan VC. 2012 NAMS/PFIZER- WULF H. UTIAN ENDOWED LECTURE. The scientific rationale for a delay after menopause in the use of conjugated equine estrogens in postmenopausal women that causes a reduction in breast cancer incidence and mortality. Menopause; 2013.
54. M. Ellis, F. Gao, F. Dehdashti, D. Jeffe, P. Marcom, and L. Carey Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study JAMA 302 2009 774 780
55. P. Lønning, P. Taylor, G. Anker, J. Iddon, and L. Wie High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy Breast Cancer Res Treat 67 2001 111 116
56. G.L. Anderson, M. Limacher, A.R. Assaf, T. Bassford, S.A. Beresford, and H. Black Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
57. G. Anderson, R. Chlebowski, A. Aragaki, L. Kuller, J. Manson, and M. Gass Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial Lancet Oncol 13 2012 476 486
58. I. Obiorah, S. Surojeet, P. Fan, and V.C. Jordan Delayed triggering of estrogen induced apoptosis that contrasts with rapid paclitaxel induced breast cancer cell death Br J Cancer 110 2014 1488 1496
59. I. Obiorah Jordan VC Differences in the rate of oestrogen-induced apoptosis in breast cancer by estradiol and the triphenylethylene bisphenol, Br J Pharmacol 2014 10.1111/bph.12762 [E pub ahead of print]
60. J. Font de Mora, and M. Brown AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor Mol Cell Biol 20 2000 5041 5047
61. H.-J. List, K.J. Lauritsen, R. Reiter, C. Powers, A. Wellstein, and A.T. Riegel Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 Is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells J Biol Chem 276 2001 23763 23768
62. T. Lahusen, R.T. Henke, B.L. Kagan, A. Wellstein, and A.T. Riegel The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer Breast Cancer Res Treat 116 2009 225 237
63. Z.Z. Hu, B.L. Kagan, E.A. Ariazi, D.S. Rosenthal, L. Zhang, and J.V. Li Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells PLoS One 6 2011 27
64. S. Bourgoin-Voillard, D. Gallo, I. Laïos, A. Cleeren, L.E. Bali, and Y. Jacquot Capacity of type I and II ligands to confer to estrogen receptor alpha an appropriate conformation for the recruitment of coactivators containing a LxxLL motif - relationship with the regulation of receptor level and ERE-dependent transcription in MCF-7 cells Biochem Pharmacol 79 2010 746 757
65. R.S. Finn Targeting Src in breast cancer Ann Oncol 19 2008 1379 1386
66. M.A. Shupnik Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation Oncogene 23 2004 7979 7989
67. S. Hiscox, L. Morgan, T. Green, D. Barrow, J. Gee, and R.I. Nicholson Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells Breast Cancer Res Treat 97 2006 263 274
68. Y. Zhao, and M.D. Planas-Silva Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity Cancer Lett 275 2009 204 212
69. F. Saad, and A. Lipton SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer Cancer Treat Rev 36 2010 177 184
70. R.S. Finn, C. Bengala, N. Ibrahim, H. Roche, J. Sparano, and L.C. Strauss Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study Clin Cancer Res 17 2011 6905 6913
71. E.L. Mayer, J.F. Baurain, J. Sparano, L. Strauss, M. Campone, and P. Fumoleau A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer Clin Cancer Res 17 2011 6897 6904
72. P. Fan, R.E. McDaniel, H.R. Kim, D. Clagett, B. Haddad, and V.C. Jordan Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines Eur J Cancer 48 2012 3488 3498
73. P. Fan, O.L. Griffith, F. Agboke, P. Anur, X. Zou, and R.E. McDaniel C-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells Cancer Res 73 2013 4510 4520
74. W.R. Harrington, S.H. Kim, C.C. Funk, Z. Madak-Erdogan, R. Schiff, and J.A. Katzenellenbogen Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action Mol Endocrinol 20 2006 491 502
75. S. Oyadomari, and M. Mori Roles of CHOP//GADD153 in endoplasmic reticulum stress Cell Death Differ 11 2003 381 389
76. D. Ron Translational control in the endoplasmic reticulum stress response J Clin Invest 110 2002 1383 1388
77. H.P. Harding, M. Calfon, F. Urano, I. Novoa, and D. Ron Transcriptional and translational control in the Mammalian unfolded protein response Annu Rev Cell Dev Biol 18 2002 575 599
78. K. Haze, H. Yoshida, H. Yanagi, T. Yura, and K. Mori Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress Mol Biol Cell 10 1999 3787 3799
79. H. Yoshida, T. Matsui, A. Yamamoto, T. Okada, and K. Mori XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor Cell 107 2001 881 891
80. M. Calfon, H. Zeng, F. Urano, J.H. Till, S.R. Hubbard, and H.P. Harding IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA Nature 415 2002 92 96
81. R.J. Kaufman Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls Genes Dev 13 1999 1211 1233
82. D. Scheuner, B. Song, E. McEwen, C. Liu, R. Laybutt, and P. Gillespie Translational control is required for the unfolded protein response and in vivo glucose homeostasis Mol cell 7 2001 1165 1176
83. H.P. Harding, Y. Zhang, A. Bertolotti, H. Zeng, and D. Ron Perk is essential for translational regulation and cell survival during the unfolded protein response Mol Cell 5 2000 897 904
84. T. Okada, H. Yoshida, R. Akazawa, M. Negishi, and K. Mori Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response Biochem J 366 2002 585 594
85. M. Matsumoto, M. Minami, K. Takeda, Y. Sakao, and S. Akira Ectopic expression of CHOP (GADD153) induces apoptosis in M1 myeloblastic leukemia cells FEBS Lett 395 1996 143 147
86. K.D. McCullough, J.L. Martindale, L.O. Klotz, T.Y. Aw, and N.J. Holbrook Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state Mol Cell Biol 21 2001 1249 1259
87. H. Puthalakath, L.A. O'Reilly, P. Gunn, L. Lee, P.N. Kelly, and N.D. Huntington ER stress triggers apoptosis by activating BH3-only protein Bim Cell 129 2007 1337 1349